Monte Rosa Therapeutics, Inc. (GLUE): Price and Financial Metrics

Monte Rosa Therapeutics, Inc. (GLUE): $7.45

0.62 (+9.08%)

POWR Rating

Component Grades













Add GLUE to Watchlist
Sign Up

Industry: Biotech



in industry

GLUE Stock Price Chart Interactive Chart >

Price chart for GLUE

GLUE Price/Volume Stats

Current price $7.45 52-week high $15.54
Prev. close $6.83 52-week low $6.05
Day low $6.81 Volume 186,600
Day high $7.60 Avg. volume 132,433
50-day MA $8.17 Dividend yield N/A
200-day MA $8.86 Market Cap 360.57M

Monte Rosa Therapeutics, Inc. (GLUE) Company Bio

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

GLUE Latest News Stream

Event/Time News Detail
Loading, please wait...

GLUE Latest Social Stream

Loading social stream, please wait...

View Full GLUE Social Stream

Latest GLUE News From Around the Web

Below are the latest news stories about MONTE ROSA THERAPEUTICS INC that investors may wish to consider to help them evaluate GLUE as an investment opportunity.

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 25, 2023

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionDisclosure of initial data from Phase 1 arm of ongoing Phase 1/2 clinical trial evaluating MRT-2359 expected in second half of 2023Nomination of multiple additional development candidates anticipated in 2023Company to present pipeline and corporate updates at 41st Annual J.P. Morgan Healthcare Conference on Wednes

Yahoo | January 9, 2023

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT.

GlobeNewswire | January 4, 2023

Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies

In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […]

Yahoo | November 17, 2022

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors –

GlobeNewswire | November 10, 2022

Read More 'GLUE' Stories Here

GLUE Price Returns

1-mo 1.78%
3-mo -14.17%
6-mo -12.15%
1-year -30.57%
3-year N/A
5-year N/A
YTD -2.10%
2022 -62.73%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5433 seconds.